On-Demand CME Videos
Atopic Dermatitis Management - Getting the Inside Track on JAKs: Online CME Activity
To learn the right answer to the following question, click "Start Activity"!
Your 26-year-old patient has a flare atopic dermatitis on 8% of her BSA with marked itching. She has used multiple courses of topical steroids and topical immunomodulators with incomplete response of her rash and itching. She is otherwise healthy and not on any birth control. What would you recommend for treating her atopic dermatitis*:
a. A short course of oral corticosteroids
b. dupilumab injection
c. oral upadacitinib
d. oral abrocitinib
e. topical ruxolitinib
This activity was recorded at the Fall Clinical Dermatology Conference October 20, 2022. This activity is supported by an educational grant from Incyte.
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
November 15, 2022
November 15, 2024
At the completion of this activity, participants should be better able to:
Review data on JAK inhibitors to treat AD
Describe how to individualize care with JAK inhibitors in patients with atopic dermatitis
Discuss strategies to prevent and manage adverse events associated with JAK inhibitors
James Del Rosso, DO
Adjunct Clinical Professor, Dermatology
Touro University Nevada
Lisa Swanson, MD
Ada West Dermatology
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: Aclaris, Amgen, Anaptys Bio, Arcutis, Athenex, Bausch (Ortho), Biorasi, Botanix, Brickell, Cara Therapeutics, Cassiopea, Dermavant, EPI Health, Galderma, Genentech, Incyte, Janssen, LEO, Lilly, Novan, Pfizer, Ralexar, Sanofi Genzyme Regeneron, Sol-Gel, SUN, Vyne
Consultant: Abbvie, Aclaris, Almirall, Amgen, Arcuits, Bausch (Ortho), Biofrontera, Biopharmx, Blue Creek, BMS, Cassiopea, Dermata, Dermavant, Encore, EPI Health, Evoummune, Ferndale, Galderma, Incyte, Jem Health, LEO, La Roche Posay, Lilly, MC2, Novan, Pfizer, Sanofi Genzyme Regeneron, Sente, Sol-Gel, Sonoma, SUN, UCB, Verrica, Vyne
Speakers’ Bureau or Honoraria: Abbvie, Aclaris, Almiral, Amgen, Bausch (Ortho), Biofrontera, Encore, EPI Health Ferndale, Galderma, Genentech, Jem Health, LEO, Lilly, Pfizer, Sanofi Genzyme Regeneron, SUN, UCB, Verrica, Vyne
Consultant: Janssen, Lilly, Ortho Dermatologics, Sanofi-Regeneron, Pfizer, LEO, Novan, Arcutis
Speakers’ Bureau or Honoraria: Ortho Dermatologics, Pfizer, Amgen, Sanofi-Regeneron, Almirall, Janssen, Lilly, Novartis, Abbvie, Incyte
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.